Multiple cardiovascular and inflammatory pathway components

The term Multiple cardiovascular and inflammatory pathway components refers to a broad and heterogeneous network of molecular signals that link systemic inflammation to the development of cardiovascular pathology. It is not a single discrete therapeutic target but rather a collective designation for several distinct pathways, most notably the NLRP3 inflammasome/IL-1/IL-6 signaling axis, which is a primary driver of atherosclerotic plaque instability and major adverse cardiovascular events (Ridker et al., 2017, NEJM). These components also include the renin-angiotensin-aldosterone system (RAAS) and various endothelial adhesion molecules like ICAM-1 and VCAM-1 that facilitate leukocyte recruitment to the vessel wall (Libby, 2021, Nature). Because this term aggregates numerous receptors, enzymes, and cytokines, it is considered an incorrect designation for a single canonical target in structured pharmacological databases. Therapeutic strategies targeting these components, such as the use of colchicine or monoclonal antibodies, aim to reduce residual inflammatory risk in patients who have already achieved optimal lipid levels (Nidorf et al., 2020, NEJM). Monitoring the activity of these pathways typically involves measuring systemic biomarkers like high-sensitivity C-reactive protein (hsCRP) (StatPearls, 2023).

Other names

Cardiovascular-inflammatory axisInflammatory signaling in cardiovascular diseaseResidual inflammatory risk pathways

Modulation of various pro-inflammatory cytokines (e.g., IL-1, IL-6), inhibition of inflammasome activation, and reduction of vascular endothelial adhesion to mitigate atherosclerotic progression and stabilize plaques.